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ABSTRACT 
 
Objective: Although osteoarthritis (OA) is a common condition in older adults, the role of OA in 
increasing cardiovascular disease (CVD) incidence is still debated. The aim of this study was to 
investigate the association between OA and the onset of CVD in a large database of American adults. 
Design: Longitudinal. 
Setting: Community-dwelling.  
Participants: People with OA or at high risk of OA.  
Measurements:. Osteoarthritis was defined as the presence of OA of the hand, knee, hip, back/neck 
or of other sites. CVD was defined as self-reported presence of heart attack, heart failure, stroke and 
other cerebral atherosclerotic conditions, and peripheral artery disease.  
Results:  A total 4,265 persons without CVD (mean age=60.8 years, females=59.2%) at baseline 
were analyzed (1,775 with OA versus 2,490 without). Over a mean of 8.2 years, according to an 
adjusted Cox’s regression analysis for 11 potential baseline confounders, study participants with OA 
of any joint had a significantly higher risk of developing CVD compared to those without OA (Hazard 
ratio (HR): =1.27; 95% CI: 1.03-1.56). The presence of hand OA was associated with a higher risk of 
developing CVD (HR=1.31; 95%CI: 1.01-1.68) with respect to those who had no OA.  Knee, hip and 
back/neck OA did not, instead, increase the risk of developing CVD. The association between OA 
and CVD was significant in the women, but not in the men.  
Conclusions: OA, in particular, when it affects the hand and is found in women, was associated with 
a higher risk of developing CVD.  
 
Keywords: osteoarthritis; cardiovascular disease; epidemiology.    
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INTRODUCTION 
 
One of the most common causes of years lived with disability are chronic musculoskeletal 
disorders.[1] Osteoarthritis (OA) accounts for a considerable amount of this burden [2], with lower 
limb OA ranked the 11th highest contributor to global disability. [2]The prevalence of OA has been 
estimated as 10% in men and 20% in women over the age of 60 years having OA across the world. 
[3]  
Increasing research is showing that OA might increase the risk of cardiovascular diseases (CVD) for 
several reasons. First, both OA and CVD share similar risk factors, namely low physical activity, 
hypertension, depression and obesity.[4-6] Secondly, compared to healthy controls, OA is often 
characterized by some degree of low-grade inflammation, another  potential CVD risk factor.[7] 
Finally, the modifications of extra-cellular matrix, typical of OA[8], could further increase the risk of 
CVD.[9]  
 
As summarized by a recent meta-analysis including 15 cross-sectional studies and more than 32 
million of participants, there is a strong association between OA and CVD.[10] Individuals with OA 
were almost three times as likely to have heart failure or coronary heart disease compared with 
matched non-osteoarthritis cohorts. [10] Conversely, the longitudinal studies are still limited and with 
contrasting results. Three studies[11-13] reported that the presence of OA significantly increased the 
onset of CVD, while another large cohort study reported no such significant association[14], 
particularly after adjusting for the presence of disability. However, these studies presented with some 
limitations  most notably for limited adjustment for potential confounders. Finally, due to the different 
criteria adopted, it was difficult to ascertain whether only symptomatic or radiological OA predicted 
the onset of CVD.   
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The purpose of this study was thus to determine whether:  i) people with OA are at increased risk of 
incident CVD compared to people without OA; ii) exists any difference among sites usually affected 
by OA (hand, hip, knee, back/neck, other) could predict CVD onset; and iii) if any difference between 
self-reported and clinical/radiological OA in predicting CVD onset.   
 
METHODS 
 
Data source and subjects 
All participants in this study were recruited as part of the ongoing, publicly and privately funded, 
multicenter, and longitudinal Osteoarthritis Initiative (OAI study) (http://www.oai.ucsf.edu/). 
Specific datasets used are those recorded during baseline and screening evaluations (November 2008) 
(V00) and those evaluating the participants until the last evaluation available (96 months; V10). 
Patients with a high risk of knee osteoarthritis were recruited from 4 clinical sites in the United States 
(Baltimore, Maryland; Pittsburgh, Pennsylvania; Pawtucket, Rhode Island; and Columbus, Ohio) 
between February 2004 and May 2006 and were eligible if they 1) had knee osteoarthritis and reported 
knee pain in a 30-d period in the past 12 mo or 2) were at high risk of developing knee osteoarthritis 
(e.g., overweight or obese, knee injury or operation, parents or siblings with total knee replacement, 
frequent knee-bending activities that increase risk, and hand or hip osteoarthritis). All of the 
participants provided written informed consent. The OAI study protocol was approved by the 
institutional review board of the OAI Coordinating Center, University of California at San Francisco. 
 
Exposure 
The diagnosis for OA in our analysis was self-reported for the most common sites usually affected 
by OA (knee, hip, hand, back/neck, and other joints) asking to participant if one doctor said that 
6 
 
he/she suffers from OA during his/her life. A summary variable ascertained as the presence of at least 
one site affected by self-reported OA was then calculated.  
 
Since for knee OA, radiological diagnosis was also ascertained, an additional analysis was undertaken 
assessing knee OA defined as a combination of the clinical reporting and assessment of pain and 
stiffness (i.e. pain, aching or stiffness in or around the knee on most days during the last year), and 
radiographical OA on the baseline fixed flexion radiograph based on the presence of tibiofemoral 
osteophytes (correspondent to Osteoarthritis Research Society International atlas grades 1-3, clinical 
center reading).   
 
Outcomes 
The main outcome of interest was the onset of CVD during the follow-up period. As for OA, CVD 
was recorded through self-reported information.  
 
We defined the development of CVD as the presence of heart attack, heart failure, unclog or bypass 
arteries in legs, and stroke, cerebrovascular accident, blood clot in brain, or transient ischemic attack. 
The presence of CVD in the OAI was recorded, other than baseline, during the V3 (24 months), V6 
(48 months) and V10 (96 months).  
 
Covariates 
A number of variables was identified from the OAI dataset to explore the relationship between OA 
and incident CVD. These included: (1) physical activity evaluated through the Physical Activity Scale 
for the Elderly, a validated scale for assessing physical activity level in the elderly.[15] The scale 
covers 12 different activities, such as walking, sports, and housework, and is scored from 0 to 400 
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and more (no maximum score has been defined); (2) race was defined as “whites” vs. others; (3) 
smoking habits as “previous/current” vs. never; (4) educational level was categorized as “degree” vs. 
others; (5) yearly income as < and missing data vs. > 50,000 $; (6) co-morbidities assessed  through 
the modified Charlson comorbidity score, with higher scores indicating an increased severity of 
conditions[16]; and (7) body mass index (BMI) recorded by a trained nurse. Among the several 
medical conditions assessed through the Charlson co-morbidity score, we reported descriptively the 
prevalence of some common diseases that could influence the association between OA and CVD, 
namely diabetes and cancer. Hypertension was diagnosed through self-reported information or in case 
of systolic blood pressure >140 and/or diastolic blood pressure > 90 mmHg. Blood pressure in the 
OAI study was measured by a trained nurse following a standard approach.   
 
Statistical analyses 
For continuous variables, normal distributions were tested using the Kolmogorov-Smirnov test. The 
data are shown as means and standard deviations (SD) for quantitative measures, and frequency and 
percentages for all discrete variables by OA presence at baseline. P-values were calculated for 
continuous variables using the independent Student T-test and for categorical parameters the chi-
square test by OA presence at baseline.  
 
Multivariate Cox’s regression models were conducted using as exposure the presence of OA and as 
outcome incident CVD at follow-up visits. People dead during follow-up period were censored. Time 
to event was calculated as time to first CVD event.  
 
Factors which reached a statistical significance between participants with OA vs. those without or 
significantly associated with CVD at follow-up (taking a p-value<0.05 as statistically significant) 
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were included. Multi-collinearity among covariates was assessed through variance inflaction factor, 
taking a cut-off of 2 as reason of exclusion, but no variable was excluded for this reason. The basic 
model was not adjusted for any confounders, while the fully adjusted model included baseline values 
of: age (as continuous); gender; race (whites vs. others); BMI (as continuous); education (degree vs. 
others); smoking habits (current and previous vs. others); yearly income (categorized as > or < 
50,000$ and missing data); PASE score (as continuous); Charlson comorbidity index; presence of 
hypertension (yes vs. no); and use of analgesic drugs (yes vs. no). Data of Cox’s regression analysis 
were reported as hazard ratios (HRs) with correspondent 95% confidence intervals (CIs).  
In secondary analyses, specific joints affected by OA (categorized as knee, hip, hand, back/neck, or 
other joints) and the presence of knee OA, defined through radiological and clinical criteria, were 
taken as exposure variables. Participants without any presence of OA were taken as reference also in 
these analyses.   
To test the robustness of our analyses, sensitivity analyses were conducted evaluating the interaction 
between the presence of self-reported and radiological/clinical diagnosis of OA and selected factor 
(e.g. gender, race, education, smoking habits, yearly income and presence/absence of diseases at 
baseline) in predicting CVD at follow-up. Gender emerged as potential moderator of our analyses 
(for interaction <0.001).  Through this data are presented also by gender.   
 
All analyses were performed using the SPSS 21.0 for Windows (SPSS Inc., Chicago, Illinois). All 
statistical tests were two-tailed and statistical significance was assumed for a p-value <0.05. 
 
RESULTS 
 
Study participants 
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At baseline, among 4,796 potentially eligible individuals, we excluded 313 had already a CVD, 21 
did not have any information regarding OA and 197 without data during follow-up evaluations, 
obtaining a final sample of 4,265 participants     
 
Baseline analyses  
Overall, 4,265 participants (1,740 Males; 2,525 Females) with a mean age of 60.8±9.1 (range: 45-79) 
years were eligible for inclusion in the current study. At baseline, 1,775 people with OA (41.6%) 
were compared with 2,490 participants without OA.   
 
The baseline characteristics of the OA and non-OA participants are summarized in the Table 1 in the 
sample as whole and divided by gender. Independently from gender, participants with OA were 
significantly older and used more frequently analgesic drugs than those without OA. In men, 
participants with OA were more frequently obese, smokers, diabetic than those without OA, whilst 
in women, participants with OA were more frequently whites, sedentary (as shown by lower PASE 
scores), more educated and with a higher presence of co-morbidities as shown by higher Charlon’s 
score (Table 1).  
 
Association between baseline osteoarthritis and incident cardiovascular disease 
After a mean period of 8.2 years, 416 individuals (9.8% of baseline population) (113 developed heart 
attack, 190 heart failure, 151 strokes or other cerebrovascular conditions, and 72 peripheral artery 
disease) developed a CVD event. The global incidence rate of CVD was 16 (95% CI: 0-41) events 
for 1000 persons-year.  
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As shown in Figure 1, the incidence of CVD was significantly higher in those having OA at baseline 
compared to those without (OA: 17; 95% CI: 0-48 vs. no OA: 14; 95% CI: 0-37/1000 events for 1000 
persons-year; p<0.001).  
 
Table 2 shows the Cox’s regression analyses by OA presence and for OA specific site. Taking those 
without any presence of OA as reference and after adjusting for 11 potential baseline confounders, 
OA was associated with a significant higher risk of CVD (HR=1.27; 95% CI: 1.03-1.56, p=0.02), 
particularly when OA affected hand (HR=1.31; 95% CI: 1.01-1.68, p=0.04). The association between 
any site OA and incident CVD remains significant in women (HR=1.50; 95% CI: 1.13-2.00, p=0.005), 
but not in men (Table 2). In women, OA affecting hip (HR=1.51; 95% CI: 1.00-2.27, p=0.048) and 
hand (HR=1.65; 95% CI: 1.21-2.24, p=0.001) increased the risk of CVD, whilst in men no site was 
at increased risk of developing CVD.  
 
Knee OA defined through radiological and clinical presence, did not show any significant association 
with incident CVD in the sample as whole (HR=0.94; 95% CI: 0.76-1.15, p=0.52), nor in men 
(HR=1.03; 95%CI: 0.76-1.34, p=0.85) or in women (HR=0.85; 95% CI: 0.64-1.14, p=0.28).  
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DISCUSSION 
 
In this large prospective study, we have demonstrated that the presence of OA at the baseline 
significantly increased the risk of CVD during follow-up period of about 27%. Among the sites 
investigated in our analysis only hand OA was associated with an increased risk of CVD in the whole 
sample whilst, in women, also hip OA increased the risk of CVD. The association of OA with CVD 
was significant only in women, suggesting important gender differences.  
 
In this cohort, OA seemed to be quite a strong predictor of the onset of CVD at follow-up. Several 
mechanisms have been suggested to explain the association between OA and CVD.[17] Firstly, the 
conditions in common between OA and CVD, such as age, hypertension and obesity. Among these 
factors, the association between OA and hypertension is relevant. Previous research has in fact 
reported that, among all potential CVD risk factors, hypertension is the most common prevalent in 
people having OA for several reasons, including alterations of extra-cellular matrix typical of OA 
that could lead firstly to hypertension and finally to CVD. [7,9] Secondly, a greater use of anti-
inflammatory drugs by people with OA could contribute to the onset of CVD.[18] However, our 
analyses were adjusted for these potential confounders, suggesting that other pathways are probably 
involved. Thirdly, OA probably promotes the onset of other potential CVD risk factors during follow-
up (e.g. physical inactivity, obesity, disability) that could contribute to the higher CVD risk in our 
association.[19] Finally, changes in extracellular matrix remodeling or an altered Wnt signaling 
transduction may play a role in the development of CVD in people with OA.[20]  
 
Previous longitudinal studies on the possible association between OA and CVD produced not 
univocal results. Whilst Nueusch et al.[11] found that OA increased the risk of CVD mortality in 
agreement with other studies [21], Hoeven et al. found no significant association between OA of the 
hand, knee or hip and CVD in 4,868 people over 55 years of age.[14] This finding is probably due to 
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the different criteria used to diagnose OA: Hoeven et al. [14] used a clinical-radiological diagnosis 
of OA, whilst we used a self-reported information regarding the presence of OA as primary analysis. 
As confirmed by our results, it is likely that only symptomatic, and not to radiographic OA, is 
associated with a higher CVD risk.  
 
Among the sites investigated in the sample as whole, only OA affecting the hand emerged as possible 
risk factor for CVD. The topic if hand OA could increase the risk of CVD is again controversial. 
Some cross-sectional studies, in fact, have shown that hand OA is associated with a higher presence 
of CVD, also in pre-clinical forms. For example in a study involving 5,342 older participants, hand 
OA was associated with a significant higher presence of carotid plaques, coronary and aortic 
calcifications, particularly in women.[22] It is known that hand OA is linked to the menopause more 
strongly than other sites[23] and the subsequent decrease in circulating endogenous estrogens, a 
feature which has also been linked to an increase in CVD rate.[24] However, some longitudinal 
studies have shown that hand OA was not associated with higher risk of CVD onset. [12,25] 
Therefore, other studies are needed to disentangle this topic. 
 
When we analyzed our data separately by gender, OA only emerged as a significant CVD risk factor 
only in women, in agreement with the literature regarding this topic.[26] Even if why the association 
between OA and CVD is significant only in women is unclear. One hypothesis is that women make 
more use of analgesic drugs for these conditions than men, because they are more sensitive to 
pain.[17] Since these drugs have an unfavorable CVD profile, it is likely that this factor may play a 
role. Another possible explanation could be extracellular matrix (ECM) remodeling after menopause 
since, before this period of life, women are at decreased CVD risk than men. It is known that ECM 
is altered in OA (particularly in the cartilage joints)[27], but this process probably involves also 
arteries and heart.[9] Since after menopause the alterations of ECM is more rapid in women than men 
due to the loss of estrogens [24], it may be that these changes make the onset of CVD more likely in 
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women than in men. Third, other researches have proposed that other pathways are probably involved 
in this gender difference, e.g. tool-like receptors (TLRs) pathways are more altered in post-
menopausal women than men[28], and play a part in both OA[29] and CVD. [28] Finally, we should 
acknowledge that men are less represented in the OAI than women and so a type II error for analyses 
regarding men is possible.  
Our findings should be considered within the limitations of our study. First, as mentioned before, the 
diagnosis of OA was self-reported, except for knee OA. Second, also the diagnosis of CVD and the 
comorbidities was self-reported and this could create a bias. The lack of data regarding medications 
could introduce another bias: for example, we found a prevalence of hypertension of 20%, whilst in 
people aging about 60 years it is estimated in about 50%.[30] Similarly, some drugs commonly used 
in the elderly (e.g. duloxetine) that could increase the risk of hypertension were not used as potential 
confounders in our analyses. Third, we don’t have any information regarding CVD mortality and 
other cardiovascular events, such as hospitalization for CVD, that our recent research has shown been 
associated with the presence of OA. [12]Fifth, people with OA at the baseline had already a higher 
prevalence of several CVD risk factors that could increase the risk of incident CVD. Although we 
have adjusted our analyses for all these factors,  a selection  bias could be not excluded. Finally, we 
did not assess any inflammatory marker, although inflammation could be associated with higher CVD 
risk.[31] Nonetheless, allowing for these caveats, our study involves a large population and the 
follow-up period seems to be appropriate for our outcome of interest. Moreover, we adjusted our 
analyses for multiple important confounders, thus strengthening our results. 
 
In conclusion, our study demonstrated that people with OA are significantly associated with an 
increased risk of the onset of CVD in middle-aged and older participants over an eight-year period. 
Since some interventions aiming to improve OA symptoms (e.g. increasing physical activity and 
weight loss reduction) seem to be effective from a cardiological perspective, further studies are 
needed to better understand if to treat OA is able to decrease CVD risk in these individuals.  
14 
 
 
ACKNOWLEDGMENTS 
 
Conflict of interest: The Authors declare that there is no conflict of interest.   
 
Funding sources: The OAI is a public-private partnership comprised of five contracts(N01-AR-2-
2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262)funded by the National 
Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the 
OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis 
Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI 
is managed by the Foundation for the National Institutes of Health. This manuscript was prepared 
using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI 
investigators, the NIH, or the private funding partners. 
 
Role of founding source: The funding sources did not have any role in in study design; in the 
collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit 
the article for publication. 
 
  
15 
 
REFERENCES 
 
1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C et al. (2013) Years lived with 
disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic 
analysis for the Global Burden of Disease Study 2010. Lancet 380:2163-96 
doi:http://dx.doi.org/10.1016/S0140-6736(12)61729-2 
2. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, Bridgett L, Williams S, Guillemin 
F, Hill CL, Laslett LL, Jones G, Cicuttini F, Osborne R, Vos T, Buchbinder R, Woolf A, 
March L (2014) The global burden of hip and knee osteoarthritis: estimates from the Global 
Burden of Disease 2010 study. Annals of the rheumatic diseases 73:1323-30 
doi:10.1136/annrheumdis-2013-204763 
3. Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC et al. (2013) Health economics in 
the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical 
and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in arthritis and 
rheumatism 43:303-13 doi:10.1016/j.semarthrit.2013.07.003 
4. Hunter DJ, Felson DT (2006) Osteoarthritis. BMJ (Clinical research ed) 332:639-42 
doi:10.1136/bmj.332.7542.639 
5. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch 
R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F (1998) Estimates 
of the prevalence of arthritis and selected musculoskeletal disorders in the United States. 
Arthritis and rheumatism 41:778-99 doi:10.1002/1529-0131(199805)41:5<778::AID-
ART4>3.0.CO;2-V 
6. Veronese N, Stubbs B, Solmi M, Smith TO, Noale M, Cooper C, Maggi S (2016) Association 
between lower limb osteoarthritis and incidence of depressive symptoms: data from the 
osteoarthritis initiative (in eng). Age and ageing doi:10.1093/ageing/afw216 
16 
 
7. Bonnet CS, Walsh DA (2005) Osteoarthritis, angiogenesis and inflammation. Rheumatology 
44:7-16 doi:10.1093/rheumatology/keh344 
8. Hardingham T (2008) Extracellular matrix and pathogenic mechanisms in osteoarthritis vol 
10. doi:10.1007/s11926-008-0006-9 
9. Ju H, Dixon IM (1996) Extracellular matrix and cardiovascular diseases. Can J Cardiol 
12:1259-67  
10. Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO (2016) Association between 
osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. European 
journal of preventive cardiology 23:938-46 doi:10.1177/2047487315610663 
11. Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P (2011) All cause and disease 
specific mortality in patients with knee or hip osteoarthritis: population based cohort study. 
BMJ (Clinical research ed) 342:d1165-d65 doi:10.1136/bmj.d1165 
12. Veronese N, Trevisan C, De Rui M, Bolzetta F, Maggi S, Zambon S, Musacchio E, Sartori L, 
Perissinotto E, Crepaldi G, Manzato E, Sergi G (2016) Association of Osteoarthritis With 
Increased Risk of Cardiovascular Diseases in the Elderly: Findings From the Progetto Veneto 
Anziano Study Cohort (in eng). Arthritis & rheumatology (Hoboken, NJ) 68:1136-44 
doi:10.1002/art.39564 
13. Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH (2013) The relationship between 
osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. 
BMJ open 3:10.1136/bmjopen-2013-002624 doi:10.1136/bmjopen-2013-002624; 
10.1136/bmjopen-2013-002624 
14. Hoeven TA, Leening MJG, Bindels PJ, Castaño-Betancourt M, van Meurs JB et al. (2014) 
Disability and not osteoarthritis predicts cardiovascular disease: a prospective population-
based cohort study. Annals of the rheumatic diseases 74:S46-S46 doi:10.1136/annrheumdis-
2013-204388 
17 
 
15. Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA (1999) The physical activity 
scale for the elderly (PASE): evidence for validity. Journal of clinical epidemiology 52:643-
51  
16. Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW (1996) Can comorbidity be measured 
by questionnaire rather than medical record review? Medical care 34:73-84  
17. Fernandes GS, Valdes AM (2015) Cardiovascular Disease and Osteoarthritis: Common 
Pathways and Patient Outcomes. European Journal of Clinical Investigation 45:n/a-n/a 
doi:10.1111/eci.12413 
18. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni 
P (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-
analysis. BMJ (Clinical research ed) 342:c7086-c86 doi:10.1136/bmj.c7086 
19. Sergi G, Veronese N, Fontana L, De Rui M, Bolzetta F, Zambon S, Corti M-C, Baggio G, 
Toffanello ED, Crepaldi G, Perissinotto E, Manzato E (2015) Pre-frailty and risk of 
cardiovascular disease in elderly men and women: the pro.v.a. study (in eng). Journal of the 
American College of Cardiology 65:976-83 doi:10.1016/j.jacc.2014.12.040 
20. Rao TP, Kühl M (2010) An updated overview on wnt signaling pathways: A prelude for more 
vol 106. doi:10.1161/CIRCRESAHA.110.219840 
21. Veronese N, Cereda E, Maggi S, Luchini C, Solmi M, Smith T, Denkinger M, Hurley M, 
Thompson T, Manzato E, Sergi G, Stubbs B (2016) Osteoarthritis and Mortality: A 
Prospective Cohort Study and Systematic Review with Meta-analysis (in English). Seminars 
in Arthritis and Rheumatism 46:160-7. doi:10.1016/j.semarthrit.2016.04.002 
22. Jonsson H, Helgadottir GP, Aspelund T, Eiriksdottir G, Sigurdsson S, Ingvarsson T, Harris 
TB, Launer L, Gudnason V (2009) Hand osteoarthritis in older women is associated with 
carotid and coronary atherosclerosis: the AGES Reykjavik study. Annals of the rheumatic 
diseases 68:1696-700 doi:10.1136/ard.2008.096289 
18 
 
23. Watt FE (2015) Hand osteoarthritis, menopause and menopausal hormone therapy. Maturitas 
83:13-18 doi:10.1016/j.maturitas.2015.09.007 
24. Bay-Jensen AC, Slagboom E, Chen-An P, Alexandersen P, Qvist P, Christiansen C, 
Meulenbelt I, Karsdal Ma (2013) Role of hormones in cartilage and joint metabolism: 
understanding an unhealthy metabolic phenotype in osteoarthritis. Menopause (New York, 
NY) 20:578-86 doi:10.1097/GME.0b013e3182745993 
25. Kluzek S, Sanchez-Santos MT, Leyland KM, Judge A, Spector TD, Hart D, Cooper C, 
Newton J, Arden NK (2015) Painful knee but not hand osteoarthritis is an independent 
predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged 
women. Annals of the rheumatic diseases:annrheumdis-2015-208056 
doi:10.1136/annrheumdis-2015-208056 
26. Hoeven TA, Kavousi M, Ikram MA, van Meurs JB, Bindels PJ, Hofman A, Franco OH, 
Bierma-Zeinstra SM (2015) Markers of atherosclerosis in relation to presence and progression 
of knee osteoarthritis: a population-based cohort study. Rheumatology (Oxford, England) 
54:1692-98 doi:10.1093/rheumatology/kev106 
27. Smiley Da, Khalil Ra (2009) Estrogenic compounds, estrogen receptors and vascular cell 
signaling in the aging blood vessels. Current medicinal chemistry 16:1863-87 
doi:10.2174/092986709788186093 
28. Poulain-Godefroy O, Le Bacquer O, Plancq P, Lecoeur C, Pattou F, Frühbeck G, Froguel P 
(2010) Inflammatory role of Toll-like receptors in human and murine adipose tissue. 
Mediators of inflammation 2010:823486-86 doi:10.1155/2010/823486 
29. Akira S, Takeda K (2004) Toll-like receptor signalling. Nature reviews Immunology 4:499-
511 doi:10.1038/nri1391 
30. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps 
SG, Roccella EJ (2005) Recommendations for blood pressure measurement in humans and 
experimental animals: Part 1: blood pressure measurement in humans: a statement for 
19 
 
professionals from the Subcommittee of Professional and Public Education of the American 
Heart Association Cou. Hypertension 45:142-61 doi:10.1161/01.HYP.0000150859.47929.8e 
31. Libby P (2006) Inflammation and cardiovascular disease mechanisms. The American journal 
of clinical nutrition 83:456S-60S  
  
20 
 
FIGURES AND TABLES 
 
Figure 1. Cumulative incidence of cardiovascular disease according to the presence or absence of 
osteoarthritis (OA) at baseline in the sample as whole.  
 
 
Notes:  
Green line indicates the subjects having OA at baseline, blue line those without.  
Values represent the number of subjects with or without OA at risk of cardiovascular disease per year 
during the follow-up period.  
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Table 1. Baseline characteristics classified according to presence or not of osteoarthritis (OA). 
 
Notes: 
P-value: ***: p<0.001; **: p<0.01; *. p<0.05 
Numbers are mean values (and standard deviations) or number (and percentages), as appropriate. 
Unless otherwise specified, p values are calculated with an independent Student T-test for continuous and with a chi-square test for categorical 
variables, respectively.  
Abbreviations: BMI: body mass index; PASE:  physical activity scale for the elderly.  
 
  
 Whole sample Men Women 
Variable 
OA 
(n=1,775) 
No OA 
(n=2,490) 
OA 
(n=626) 
No OA 
(n=1,114) 
OA 
(n=1,149) 
No OA 
(n=1,376) 
Age (years) 62.3 (8.6) 59.8 (9.1)*** 61.7 (9.2) 59.6 (9.4)*** 62.6 (8.6) 60.0 (8.9)*** 
White race (n, %) 1501 (84.6) 1937 (77.9)*** 541 (86.6) 937 (84.2) 960 (83.6) 1000 (72.7)*** 
BMI (Kg/m2) 28.7 (4.8) 28.4 (4.8)** 29.1 (4.1) 28.6 (4.1)* 28.6 (5.2) 28.2 (5.2) 
PASE (points) 157.5 (81.4) 167.1 (83.0)*** 176.8 (88.3) 181.2 (88.5) 147.0 (75.5) 155.7 (76.4)** 
Smoking (previous/current) 853 (48.6) 1099 (44.8)* 335 (54.3) 500 (45.5)** 518 (45.5) 599 (44.2) 
Degree (n, %) 586 (33.3) 731 (29.6)** 245 (39.6) 400 (36.3) 341 (29.8) 331 (24.3)** 
Yearly income (<50,000 $) 654 (36.8) 846 (34.0) 161 (25.7) 279 (25.0) 493 (42.9) 567 (41.2) 
Medical conditions       
Diabetes (n, %) 125 (7.2) 162 (6.7) 56 (9.1) 70 (6.5)* 69 (6.1) 92 (6.9) 
Cancer (n, %) 87 (4.9) 114 (4.6) 41 (6.5) 64 (5.8) 46 (4.0) 50 (3.6) 
Hypertension (n, %) 359 (20.2) 217 (20.8) 144 (23.0) 262 (23.5) 215 (18.7) 255 (18.5) 
Charlson co-morbidity score 0.32 (0.71) 0.26 (0.71)*** 0.32 (0.76) 0.26 (0.76) 0.33 (0.68) 0.26 (0.66)*** 
Use of analgesic drugs (n, %) 930 (52.5) 735 (29.7)*** 293 (47.0) 305 (27.6)*** 637 (55.5) 430 (31.4)*** 
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Table 2: Associations between presence of osteoarthritis at the baseline and incident cardiovascular diseases.  
 
Unless otherwise specified, data are presented as hazard ratios and 95% confidence intervals. 
Bold values are significant results (p<0.05) after fully-adjustment.  
Notes: 
* Fully-adjusted model included baseline values of: age (as continuous); gender; race (whites vs. others); body mass index (as continuous); education 
(degree vs. others); smoking habits (current and previous vs. others); yearly income (categorized as > or < 50,000$ and missing data); physical activity 
scale for the elderly (as continuous); Charlson co-morbidity index (as continuous); presence of hypertension (yes vs. no); use of analgesic drugs (yes 
vs. no).  
** Those without any presence of osteoarthritis were taken as reference in all analyses.   
 Whole sample Men Women 
Variable 
Unadjusted 
hazard ratio 
(95%CI) 
Fully-adjusted *  
Model 
hazard ratio 
(95%CI) 
Unadjusted 
hazard ratio 
(95%CI) 
Fully-adjusted *  
Model 
hazard ratio 
(95%CI) 
Unadjusted 
hazard ratio 
(95%CI) 
Fully-adjusted *  
Model 
hazard ratio 
(95%CI) 
Presence of OA 
1.34 (1.10-1.63) 
P=0.003 
1.27 (1.03-1.56) 
P=0.02 
1.20 (0.89-1.60) 
P=0.23 
1.07 (0.79-1.45) 
P=0.66 
1.58 (1.20-2.09) 
P=0.001 
1.50 (1.13-2.00) 
P=0.005 
Knee OA 
1.13 (0.90-1.42) 
P=0.30 
1.04 (0.82-1.32) 
P=0.74 
1.04 (0.74-1.46) 
P=0.82 
0.97 (0.69-1.389 
P=0.88 
1.21 (0.89-1.65) 
P=0.22 
1.10 (0.80-1.50) 
P=0.58 
Hip OA 
1.48 (1.06-2.06) 
P=0.02 
1.30 (0.92-1.82) 
P=0.13 
1.29 (0.70-2.37) 
P=0.42 
1.00 (0.54-1.87) 
P=0.99 
1.69 (1.14-2.53) 
P=0.01 
1.51 (1.00-2.27) 
P=0.048 
Hand OA 
1.42 (1.12-1.81) 
P=0.004 
1.31 (1.01-1.68) 
P=0.04 
1.02 (0.62-1.69) 
P=0.93 
0.80 (0.48-1.33) 
P=0.39 
1.82 (1.36-2.44) 
P<0.001 
1.65 (1.21-2.24) 
P=0.001 
Back/neck OA 
1.34 (1.05-1.70) 
P=0.02 
1.21 (0.95-1.55) 
P=0.12 
1.30 (0.89-1.92) 
P=0.18 
1.10 (0.74-1.64) 
P=0.63 
1.45 (1.07-1.97) 
P=0.01 
1.32 (0.96-1.81) 
P=0.09 
Other joints OA 
1.33 (0.97-1.80) 
P=0.08 
1.31 (0.95-1.80) 
P=0.10 
1.36 (0.83-2.25) 
P=0.23 
1.33 (0.80-2.21) 
P=0.27 
1.36 (0.92-2.03) 
P=0.13 
1.30 (0.87-1.96) 
P=0.20 
